Načítá se...
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
The progressive nature of type 2 diabetes necessitates that treatment is intensified as the disease advances. Several studies have shown that basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) can be used in combination to successfully improve glycemic control and this combinatio...
Uloženo v:
| Vydáno v: | Expert Rev Endocrinol Metab |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4894076/ https://ncbi.nlm.nih.gov/pubmed/27335581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17446651.2016.1113129 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|